Tag: TME
TME Pharma NV: financial visibility until July
By Alexandra Saintpierre Published on 04/25/2024 at 8:32 p.m. Photo credit © TME Pharma (Boursier.com) — TME…
TME Pharma: news regarding patients with glioblastoma
By Hector Chaunu Published on 04/23/2024 at 08:09 a.m. Photo credit © ChaunuPictures (Boursier.com) — TME Pharma…
TME Pharma: FDA Grants Fast Track Designation for NOX-A12
(Boursier.com) — TME Pharmaa biotechnology company specializing in the development of new therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces that the US Food and…
TME Pharma: Fast Track designation in glioblastoma – 04/03/2024 at 1:27 p.m.
(CercleFinance.com) – TME Pharma announces that the US FDA has granted Fast Track designation to its NOX-A12, in combination with radiotherapy and bevacizumab, for use in the treatment of aggressive…
TME PHARMA – The US FDA grants Fast Track designation for NOX-A12, TME Pharma’s lead program, in brain cancer – 04/02/2024 at 8:30 p.m.
TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces that…
TME Pharma: visibility extended to early July after BSA exercise – 02/23/2024 at 09:57
(AOF) – TME Pharma announces that the exercise of 8.5 million Y warrants triggered the issuance of 3.4 million new shares for gross proceeds of around 854,000 euros. The biotech…
TME PHARMA announces the end of the convertible bond program following the success of a financing of 1.48 million euros intended to repurchase all the convertible debt still in circulation – 02/09/2024 at 08 :00
To receive all of the company’s financial communications in real time, please register directly by email to the following address: [email protected] TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology…
TME Pharma: success against brain cancer, a file submitted to the FDA – 02/02/2024 at 09:44
(AOF) – TME Pharma announces that the final median overall survival for patients with recently diagnosed glioblastoma (brain cancer) treated with its product NOX-A12 has reached 19.9 months. The biotech…
TME PHARMA – Update of the number of shares and warrants in circulation following the first exercise period of Y warrants – 01/23/2024 at 6:30 p.m.
Exercise of 974,365 Y warrants resulting in the issuance of 389,746 new ordinary shares and 389,746 Z warrants Berlin, Germany, January 23, 2024, 6:00 p.m. CET – TME Pharma NV…
TME PHARMA ANNOUNCES THE SUCCESS OF ADVISORY MEETING WITH THE US FDA ON THE DEVELOPMENT OF NOX-A12 IN BRAIN CANCER – 01/09/2024 at 6:00 p.m.
• A constructive meeting with the FDA provided feedback and clear guidance on key aspects of the continued development of NOX-A12 combinations for the treatment of glioblastoma.• Preparatory work is…
TME Pharma: constructive meeting with the FDA for NOX-A12 – 01/09/2024 at 6:18 p.m.
(AOF) – TME Pharma announces the success of the advisory meeting with the FDA on the development of NOX-A12 against brain cancer. Based on the information received, TME Pharma confirms…
TME Pharma: constructive meeting with the FDA for NOX-A12
(AOF) – TME Pharma announces the success of the advisory meeting with the FDA on the development of NOX-A12 against brain cancer. Based on the information received, TME Pharma confirms…